Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Genmab A/S
  6. News
  7. Summary
    GMAB   DK0010272202

GENMAB A/S

(GMAB)
  Report
Delayed Nasdaq Copenhagen  -  10:59 2022-12-02 am EST
3277.00 DKK   -0.55%
11/29Genmab A/s : has published its Articles of Association
PU
11/23Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
GL
11/23Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Genmab A/S - Completion of share buy-back program

09/02/2022 | 09:08am EST

COPENHAGEN - Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on August 31, 2022.

On June 17, 2022 Genmab announced the initiation of a share buy-back program to mitigate dilution from warrant exercises and to honor our commitments under our Restricted Stock Units program.

The share buy-back program was expected to be completed no later than August 31, 2022 and comprised up to 370,000 shares.

Genmab's accumulated share buy-back from June 20, 2022 to August 31, 2022 amounts to 370,000 shares at a total cost of DKK 907.49 million. The announced share buy-back program has thus been completed.

Following these transactions, Genmab holds 599,883 shares as treasury shares, corresponding to 0.91% of the total share capital and voting rights.

The share buy-back program is undertaken in accordance with Regulation (EU) No. 596/2014 ('MAR') and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the 'Safe Harbour Regulation.' Further details on the terms of the share buy-back program can be found in our company announcement no. 22 dated June 17, 2022.

About Genmab

Genmab is an international biotechnology company with a core purpose to improve the lives of people with cancer. For more than 20 years, Genmab's vision to transform cancer treatment has driven its passionate, innovative and collaborative teams to invent next-generation antibody technology platforms and leverage translational research and data sciences, fueling multiple differentiated cancer treatments that make an impact on people's lives. To develop and deliver novel therapies to patients, Genmab has formed 20+ strategic partnerships with biotechnology and pharmaceutical companies. Genmab's proprietary pipeline includes bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates.

Genmab is headquartered in Copenhagen, Denmark with locations in Utrecht, the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.

Contact:

Marisol Peron

Tel: +1 609 524 0065

Email: mmp@genmab.com

This Company Announcement contains forward looking statements. The words 'believe', 'expect', 'anticipate', 'intend' and 'plan' and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about GENMAB A/S
11/29Genmab A/s : has published its Articles of Association
PU
11/23Transactions with shares and linked securities in Genmab A/S made by managerial employe..
GL
11/23Transactions with shares and linked securities in Genmab A/S made by managerial employe..
GL
11/22Genmab Announces U.S. Food and Drug Administration Accepts for Priority Review Biologic..
AQ
11/22Abbvie - U.S. FDA Accepts for Priority Review the Biologics License Application for Epc..
AQ
11/21Transactions with shares and linked securities in Genmab A/S made by managerial employe..
GL
11/21Transactions with shares and linked securities in Genmab A/S made by managerial employe..
GL
11/21Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to..
GL
11/21AbbVie Says Epcoritamab Obtains FDA Priority Review for Treatment of Large B-Cell Lymph..
MT
11/21US FDA Accepts Genmab's Biologics License Application for Epcoritamab for Priority Revi..
MT
More news
Analyst Recommendations on GENMAB A/S
More recommendations
Financials
Sales 2022 14 130 M 1 993 M 1 993 M
Net income 2022 6 931 M 978 M 978 M
Net cash 2022 22 558 M 3 182 M 3 182 M
P/E ratio 2022 31,1x
Yield 2022 -
Capitalization 214 B 30 178 M 30 178 M
EV / Sales 2022 13,5x
EV / Sales 2023 11,2x
Nbr of Employees 1 560
Free-Float 97,9%
Chart GENMAB A/S
Duration : Period :
Genmab A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENMAB A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 3 277,00 DKK
Average target price 2 992,00 DKK
Spread / Average Target -8,70%
EPS Revisions
Managers and Directors
Jan G. J. van de Winkel President & Chief Executive Officer
Anthony Pagano Chief Financial Officer & Executive Vice President
Deirdre P. Connelly Chairman
Tahamtan Ahmadi Chief Medical Officer & Executive Vice President
Martin Schultz Non-Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GENMAB A/S24.60%30 178
VERTEX PHARMACEUTICALS46.34%82 493
REGENERON PHARMACEUTICALS, INC.20.54%81 852
BIONTECH SE-34.16%41 250
WUXI APPTEC CO., LTD.-34.47%32 173
ARGENX SE22.14%22 340